Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
Mechanisms of Resistance to Antibody–Drug ConjugatesRachel O. Abelman, Aditya Bardia, Bogang Wu et al.|Cancers|2023Cited by 135
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast CancerTanya T. Kwan, Shyamala Maheswaran, Aditya Bardia et al.|Cancer Discovery|2018Cited by 116
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Giuseppe Viale et al.|Journal of Clinical Oncology|2019Cited by 82
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Sara M. Tolaney et al.|Annals of Oncology|2023Cited by 77